Daichi Fujimoto

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Brain Metastases

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Investigational new drugs

Cancer research communications

Respirology case reports

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications (2024)
Masanori Tanaka, Daichi Fujimoto, Hiroaki Akamatsu, Hiromitsu Sumikawa, Nobuyuki Yamamoto
Radiographic findings useful for diagnosis of primary chest wall lymphoma without preceding pleural disease: A case report. Respirology case reports 10 (9) (2022)
Yuki Sato, Go Saito, Daichi Fujimoto
Histologic transformation in lung cancer: when one door shuts, another opens. Therapeutic advances in medical oncology 14 (2022)
Mihoko Imaji, Daichi Fujimoto, Mai Kato, Masanori Tanaka, Katsuyuki Furuta, Nobuyuki Yamamoto
Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature. Respirology case reports 9 (5) (2021)
Takeya Sugimoto, Daichi Fujimoto, Yuki Sato, Motohiro Tamiya, Takashi Yokoi, Akihiro Tamiya, Shunichiro Iwasawa, Akito Hata, Junji Uchida, Yasushi Fukuda, Satoshi Hara, Masaki Kanazu, Katsuya Hirano, Masaki Kokubo, Nobuyuki Yamamoto
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. Investigational new drugs 39 (3) (2021)
Kazutaka Hosoya, Daichi Fujimoto, Hayato Kawachi, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Shinya Hiraoka, Masaki Kokubo, Keisuke Tomii
Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer chemotherapy and pharmacology 84 (2) (2019)
Hayato Kawachi, Daichi Fujimoto, Takeshi Morimoto, Kazutaka Hosoya, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. Investigational new drugs 37 (6) (2019)
Atsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, Kei Irie, Shoji Fukushima, Keisuke Tomii
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. Investigational new drugs 38 (4) (2019)
Ryosuke Hirabayashi, Daichi Fujimoto, Yukari Satsuma, Masaki Hirabatake, Keisuke Tomii
Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Investigational new drugs 36 (5) (2018)